AllianceBernstein Announces November 30, 2014 Assets Under Management
PR Newswire - Wed Dec 10, 3:08PM CST
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that preliminary assets under management increased to $481 billion during November 2014 from $477 billion at the end of October. The 0.8% increase was due to market appreciation and total firmwide net inflows during the month. By channel, net flows were positive for Institutions, flat for Private Client and negative for Retail.
AB: 25.74 (+0.55)
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development
GlobeNewswire - Fri Nov 28, 10:58AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.
AB: 25.74 (+0.55)
AB Science: Web conference on masitinib in asthma - Safety and Efficacy Update
GlobeNewswire - Tue Nov 25, 10:55AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
AB: 25.74 (+0.55)
AllianceBernstein Announces October 31, 2014 Assets Under Management
PR Newswire - Fri Nov 14, 7:20AM CST
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that preliminary assets under management increased to $477 billion during October 2014 from $473 billion at the end of September. The 1% increase was due to market appreciation during the month, partly offset by firmwide net outflows. By channel, net flows were negative for Institutions and flat for Retail and Private Client.
AB: 25.74 (+0.55)
AllianceBernstein Holding's (AB) CEO Peter Kraus Presents at Bank of America Merrill Lynch Banking & Financial Services Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:45PM CST
AB: 25.74 (+0.55)
AB Science: The Data and Safety Monitoring Board recommends the continuation of the phase 2 study with masitinib in advanced hepatocellular carcinoma
GlobeNewswire - Wed Nov 12, 10:50AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 2 study of masitinib in advanced hepatocellular carcinoma based upon review of the latest safety and efficacy data. The DSMB was created as part of the Company's clinical study evaluating masitinib in the treatment of advanced hepatocellular carcinoma.
AB: 25.74 (+0.55)
Post Earnings Update: AllianceBernstein Has Climbed 3.0% Higher in Past 2 Weeks (AB)
Comtex SmarTrend(R) - Mon Nov 10, 1:44PM CST
Two weeks ago on October 23rd, 2014 AllianceBernstein (NYSE:AB) reported earnings and analysts, on average, expected earnings of $0.44 on sales of $758.0 million. AllianceBernstein actually reported earnings of $0.45 per share on sales of $0.0 thousand, beating EPS estimates by $0.01 and missing revenue estimates by $758.0 million. Shares of AllianceBernstein have climbed from $25.49 to $26.25, representing a gain of 3.0% since the company reported earnings 18 days ago.
AB: 25.74 (+0.55)
Peter S. Kraus, Chairman and Chief Executive Officer, to Participate in the Bank of America Merrill Lynch 2014 Banking & Financial Services Conference on November 12
PR Newswire - Wed Nov 05, 11:16AM CST
AllianceBernstein today announced that Peter S. Kraus, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch 2014 Banking & Financial Services Conference on Wednesday, November 12, in a session that begins at 1:30 p.m. (ET) in New York.
AB: 25.74 (+0.55)
AB Science : Web conference on Masitinib in mastocytosis
GlobeNewswire - Fri Oct 31, 11:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
AB: 25.74 (+0.55)
AB Science: publication of preclinical data on the neuroprotective effect of masitinib
GlobeNewswire - Thu Oct 30, 12:13PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in ischemic stroke. Entitled, 'Neuroprotective effect of masitinib in rats with postischemic stroke' this article and its accompanying supplementary information are freely accessible online from the peer-reviewed journal Naunyn-Schmiedeberg's Archives of Pharmacology: http://link.springer.com/article/10.1007%2Fs00210-014-1061-6
AB: 25.74 (+0.55)
AllianceBernstein Holding's (AB) CEO Peter Kraus on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 6:18PM CDT
AB: 25.74 (+0.55)
AllianceBernstein Holding L.P. (AB) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 23, 6:55AM CDT
AB: 25.74 (+0.55)
More on AllianceBernstein results
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 6:47AM CDT
AB: 25.74 (+0.55)
AllianceBernstein beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 6:21AM CDT
AB: 25.74 (+0.55)
AllianceBernstein Holding L.P. Announces Third Quarter Results
PR Newswire - Thu Oct 23, 6:10AM CDT
AllianceBernstein L.P. ("AllianceBernstein"
AB: 25.74 (+0.55)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:30PM CDT
CRS: 48.03 (-0.07), CAM: 50.11 (-0.19), LAZ: 50.95 (-0.37), JAH: 47.91 (+0.10), ASPS: 33.81 (+4.37), BBW: 19.35 (+0.25), LO: 63.60 (+0.16), CAB: 51.06 (-0.12), CFX: 52.40 (-0.35), FAF: 34.30 (+0.63), KKR: 23.14 (+0.24), AEP: 61.31 (+1.20), DNKN: 41.85 (-0.13), DO: 38.66 (-0.62), JAKK: 6.81 (-0.27), AAL: 51.43 (+1.22), DAN: 21.43 (-0.02), CAT: 93.72 (+0.22), CSH: 22.16 (-0.46), LSTR: 74.53 (+0.66), BHE: 25.50 (+0.21), ARG: 117.56 (-0.42), AVT: 43.83 (+0.15), ALV: 106.19 (-0.42), ALK: 58.72 (+1.97), BKU: 29.06 (-0.24), CELG: 109.60 (+3.48), CWEI: 63.72 (-0.80), BCC: 36.29 (+0.26), HERO: 1.05 (-0.02), AB: 25.74 (+0.55), DGX: 67.94 (-0.16), ALXN: 181.96 (+3.09), CHKP: 80.44 (+0.51), MDP: 53.04 (-0.89), ACAT: 32.79 (-0.83), GRUB: 35.65 (-0.12), JBLU: 15.50 (+0.21), CLI: 19.06 (-0.03), CVE: 20.70 (-0.25), CCE: 45.10 (-0.23), LUV: 41.66 (+0.68), DPS: 73.48 (+0.03), IVC: 16.80 (+0.20), GMT: 57.30 (-0.32), BC: 51.01 (+0.68), JNS: 16.38 (+0.38), DLX: 62.88 (+0.17), CMS: 35.69 (+0.81), LTM: 55.87 (+0.36), CS: 25.95 (-0.01), LLY: 70.16 (+0.42), BMS: 45.96 (-0.12), IMAX: 30.49 (+0.35), EQT: 77.44 (-0.97), GPI: 89.75 (+0.41), EQM: 88.80 (+1.60), GM: 33.43 (-0.13), CRI: 84.50 (-0.13), CMCSA: 58.07 (+0.17), HUB.B: 108.86 (+0.40)
Buy-Rated Dividend Stocks In The Top 3: AB, CRT, HRZN
at The Street - Mon Oct 20, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
CRT: 18.91 (-0.53), AB: 25.74 (+0.55), HRZN: 13.92 (-0.07)
AllianceBernstein Expands its Liquid Alternatives Platform with Three New Funds: Credit Long/Short, Multi-Manager Alternative Strategies and Long/Short Multi-Manager
PR Newswire - Wed Oct 15, 10:06AM CDT
AllianceBernstein L.P. (AllianceBernstein), announced today it has launched three new liquid alternative mutual funds, Credit Long/Short (ALASX), Multi-Manager Alternative Strategies Fund (ALATX) and Long/Short Multi-Manager Fund (LSAMX), as it continues to broaden its array of U.S. retail offerings.
AB: 25.74 (+0.55)
AllianceBernstein Holding is Now Oversold (AB)
MarketNewsVideo.com - Fri Oct 10, 3:31PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
AB: 25.74 (+0.55)
AllianceBernstein Announces September 30, 2014 Assets Under Management
PR Newswire - Fri Oct 10, 7:40AM CDT
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that preliminary assets under management decreased to $473 billion during September 2014 from $486 billion at the end of August. The vast majority of the 2.7% decrease was attributable to market depreciation, including the negative impact of foreign exchange movements, though total net outflows during the month contributed as well. By channel, net flows were negative for Retail and Institutions and positive for Private Client.
AB: 25.74 (+0.55)